Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma

Citations Over TimeTop 10% of 2014 papers

Abstract

The structure of LX7101, a dual LIM-kinase and ROCK inhibitor for the treatment of ocular hypertension and associated glaucoma, is disclosed. Previously reported LIM kinase inhibitors suffered from poor aqueous stability due to solvolysis of the central urea. Replacement of the urea with a hindered amide resulted in aqueous stable compounds, and addition of solubilizing groups resulted in a set of compounds with good properties for topical dosing in the eye and good efficacy in a mouse model of ocular hypertension. LX7101 was selected as a clinical candidate from this group based on superior efficacy in lowering intraocular pressure and a good safety profile. LX7101 completed IND enabling studies and was tested in a Phase 1 clinical trial in glaucoma patients, where it showed efficacy in lowering intraocular pressure.

Related Papers

• → A Dose-Response Study of the Effect of Levobunolol on Ocular Hypertension(1983)37 cited
• Lack of long-term drift in timolol's effectiveness in patients with ocular hypertension.(2001)
• → Lack of long-term drift in timolol’s effectiveness in patients with ocular hypertension(2002)5 cited
• → Potential effects of systematic errors in intraocular pressure measurements on screening for ocular hypertension(2013)3 cited
• → The efficacy of the combination of I-moprolol and dipivefrin in reducing the intraocular pressure in primary open-angle glaucoma or in ocular hypertension(1994)3 cited